Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs.

The French EA reform contributed to enabling rapid access to innovations in a wide range of indications for oncology patients. However, the findings highlight ongoing challenges in financial sustainability, warranting continued evaluation and adjustments.